Regulation of Intestinal Flora by Compound Probiotics in Patients With Chronic Hepatitis B - Trial NCT06221605
Access comprehensive clinical trial information for NCT06221605 through Pure Global AI's free database. This phase not specified trial is sponsored by Wecare Probiotics Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Wecare Probiotics Co., Ltd.
Timeline & Enrollment
N/A
Mar 01, 2024
Apr 01, 2025
Primary Outcome
Test the level of HBV infection in chronic hepatitis B patients
Summary
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV
 infection levels and regulating intestinal flora in patients with chronic hepatitis B.
 
 The main question it aims to answer is:
 
 • Conventional antiviral therapy combined with a 6-month probiotic intervention was used to
 evaluate the clinical efficacy of reducing HBV infection levels (HBeAg, HBsAg, and HBV DNA
 levels) and regulating gut microbiota.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06221605
Non-Device Trial